Phase IIIEnrolling✓ PAG Endorsed by Alzheimer's Association

Lecanemab Long-Term Safety and Efficacy in Early Alzheimer's Disease

Eisai / Biogen·NCT05923156·Alzheimer's Disease

Duration

30 months

Cost

Free to Patients

Phase

Phase III

Closes

Dec 2026

About This Trial

Long-term follow-up study evaluating lecanemab (Leqembi) safety and cognitive benefit in early Alzheimer's patients.

Trial Locations

Boston, MA

San Francisco, CA

Mayo Clinic, MN

Eligibility & What to Expect

Condition focus: Alzheimer's Disease

Available in: US

All study medications and visits are provided at no cost to participants

Your health data is protected under HIPAA / GDPR / UAE PDPL regulations

You may withdraw from the trial at any time without penalty

Specific eligibility criteria (age ranges, lab values, prior medications) will be confirmed by the study coordinator after you express interest.

Patient Advocacy Endorsed

Alzheimer's Association endorses this trial

This trial has been reviewed and endorsed by Alzheimer's Association. PAG endorsement means patient advocates have evaluated the trial design, risk-benefit profile, and patient-friendliness of this study.

Trial Summary

NCT NumberNCT05923156

SponsorEisai / Biogen

PhasePhase III

Duration30 months

ClosesDec 2026

ConditionAlzheimer's Disease